PD-1 Non-Small Cell Lung Cancer Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The PD-1 Non-Small Cell Lung Cancer market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Regeneron Pharmaceuticals, Sanofi, Bavarian Nordic,, Chengdu MedGenCell Co. Ltd., Merck Sharp & Dohme LLC, Dynavax Technologies Corporation, BeiGene, Tesaro Inc., Bristol-Myers Squibb

[Nevada, United States] - DelveInsight's "PD-1 Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of PD-1 Non-Small Cell Lung Cancer, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the PD-1 Non-Small Cell Lung Cancer Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/pd-1-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the PD-1 Non-Small Cell Lung Cancer Market Report:
The PD-1 Non-Small Cell Lung Cancer market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In August, 2024: Iovance Biotherapeutics, Inc. announced a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).
In August, 2024: Tango Therapeutics, Inc announced that the goal of their clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation.
In August, 2024: Merck Sharp & Dohme LLC announced that a study evaluating the efficacy and safety of MK-1084 with pembrolizumab as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%.
In August, 2024: Novartis announced that their study aims to assess the antitumor activity and safety of JDQ443 single-agent as first-line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor a KRAS G12C mutation and a PD-L1 expression < 1% regardless of STK11 mutation status (cohort A), or a PD-L1 expression ≥ 1% and an STK11 co-mutation (cohort B).
In August, 2024: AstraZeneca announced that their study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.
The total number of incident cases of NSCLC in the 7MM was nearly 524,000 cases in 2023 and is projected to increase during the forecasted period.
In 2023, the incidence of NSCLC cases in the United States was~56% in males and~ 44% in females.
Key PD-1 Non-Small Cell Lung Cancer Companies are as follow: MSD, Bristol-Myers Squibb/Ono Pharmaceutical, Genentech/ Hoffmann-La Roche, CStone, BeiGene, Daiichi Sankyo/AstraZeneca Gilead Sciences, GlaxoSmithKline, and others
Key PD-1 Non-Small Cell Lung Cancer Therapies are as follows: KEYTRUDA, OPDIVO, TECENTRIQ, IMFINZI, TRODELVY, TIZVENI, JEMPERLI,Sugemalimab, Datopotamab Deruxtecan, Ociperlimab, and others
Launching multiple stage PD-1 Non-Small Cell Lung Cancer pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed PD-1 Non-Small Cell Lung Cancer market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

PD-1 Non-Small Cell Lung Cancer Overview:
NSCLC is the most prevalent form of lung cancer, representing about 85% of all lung cancer cases. Unlike NSCLC, untreated SCLC can be fatal within weeks. Standard treatment outcomes for NSCLC are generally poor, except in cases where the cancer is highly localized. Tumor cells can overexpress PD-L1, enabling them to evade the immune system. In NSCLC, PD-(L)1 expression, measured as the percentage of viable tumor cells with membranous staining (tumor proportion score, TPS), serves as a predictive biomarker for response to immune checkpoint inhibitors.

PD-1 Non-Small Cell Lung Cancer Pipeline Development Activities:
The landscape of non-small cell lung cancer (NSCLC) treatment is rapidly evolving, particularly with the advancement of PD-1 inhibitors. This class of immunotherapy has shown significant promise in improving outcomes for patients with advanced NSCLC. Here, we explore the latest pipeline developments related to PD-1 therapies, highlighting key clinical trials, emerging therapies, and potential market entrants.

For more information about PD-1 Non-Small Cell Lung Cancer companies working in the treatment market, visit https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

PD-1 Non-Small Cell Lung Cancer Market Insights
The PD-1 inhibitor market for non-small cell lung cancer (NSCLC) is witnessing significant growth, driven by increasing incidence rates, advancements in treatment protocols, and the ongoing development of innovative therapies. Recent insights reveal a transformative landscape that is reshaping patient outcomes and market dynamics.
The global market for PD-1 inhibitors in NSCLC is projected to reach approximately $XX billion by 2025, with a robust compound annual growth rate (CAGR) of XX% driven by rising patient demand and expanding therapeutic options.
Several new PD-1 inhibitors are in late-stage development, including Camrelizumab and Tislelizumab, which show promising efficacy in clinical trials. These developments are set to enhance the competitive landscape and provide patients with more choices.
North America remains the largest market for PD-1 inhibitors due to high incidence rates of NSCLC and advanced healthcare infrastructure. Meanwhile, the Asia-Pacific region is emerging as a key growth area, propelled by rising healthcare access and awareness.

PD-1 Non-Small Cell Lung Cancer Drugs Uptake
Zimberelimab is an anti-programmed cell death protein-1 (PD-1) monoclonal antibody being developed by Gloria Biosciences, Arcus Biosciences and Taiho Pharmaceutical Co. for the treatment of various cancers including cervical cancer, non-small cell lung cancer and classical Hodgkin's lymphoma.
PD-1 inhibitors, such as pembrolizumab (Keytruda) and nivolumab (Opdivo), are rapidly gaining traction as first-line therapies for advanced NSCLC. Recent data indicate that the adoption rate has increased by XX% over the past year, reflecting their effectiveness in improving patient survival rates.
New entrants, such as camrelizumab and tislelizumab, are showing promise in clinical trials and are anticipated to enhance market competition. Early-stage uptake data suggest these therapies could capture a significant share of the market in the coming years.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

PD-1 Non-Small Cell Lung Cancer Therapies and Key Companies:
KEYTRUDA (pembrolizumab): Merck
OPDIVO (nivolumab): Bristol-Myers Squibb/Ono Pharmaceutical
TECENTRIQ (atezolizumab): Genentech/ Hoffmann-La Roche
LIBTAYO (cemiplimab-rwlc): Regeneron/Sanofi
TIZVENI (tislelizumab): BeiGene
Sugemalimab (CS1001): CStone
Datopotamab Deruxtecan: Daiichi Sankyo/AstraZeneca
Ociperlimab + Tislelizumab: BieGene
TRODELVY (sacituzumab govitecan) + pembrolizumab: Gilead Sciences
JEMPERLI (dostarlimab): GlaxoSmithKline

PD-1 Non-Small Cell Lung Cancer Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2019 to 2032. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic PD-1 Non-Small Cell Lung Cancer.

For more information about PD-1 Non-Small Cell Lung Cancer companies working in the treatment market, visit: https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

PD-1 Non-Small Cell Lung Cancer Epidemiology Segmentation:
The PD-1 Non-Small Cell Lung Cancer market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
PD-1 Non-Small Cell Lung Cancer Total Prevalence
PD-1 Non-Small Cell Lung Cancer Prevalent Cases by severity
PD-1 Non-Small Cell Lung Cancer Gender-specific Prevalence
PD-1 Non-Small Cell Lung Cancer Diagnosed Cases of Episodic and Chronic
PD-1 Non-Small Cell Lung Cancer Market Drivers and Barriers:
The PD-1 Non-Small Cell Lung Cancer Market Forecast report highlights key drivers and barriers shaping the PD-1 Non-Small Cell Lung Cancer market dynamics, providing insights into factors influencing growth and challenges that may be encountered.

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the PD-1 Non-Small Cell Lung Cancer Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key PD-1 Non-Small Cell Lung Cancer Companies: MSD, Bristol-Myers Squibb/Ono Pharmaceutical, Genentech/ Hoffmann-La Roche, CStone, BeiGene, Daiichi Sankyo/AstraZeneca Gilead Sciences, GlaxoSmithKline, and others
Key PD-1 Non-Small Cell Lung Cancer Therapies: KEYTRUDA, OPDIVO, TECENTRIQ, IMFINZI, TRODELVY, TIZVENI, JEMPERLI,Sugemalimab, Datopotamab Deruxtecan, Ociperlimab, and others
PD-1 Non-Small Cell Lung Cancer Therapeutic Assessment: Current marketed and emerging therapies
PD-1 Non-Small Cell Lung Cancer Market Dynamics: PD-1 Non-Small Cell Lung Cancer Market drivers and PD-1 Non-Small Cell Lung Cancer barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
PD-1 Non-Small Cell Lung Cancer Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of PD-1 Non-Small Cell Lung Cancer market outlook, drug uptake, treatment scenario, and epidemiology trends: https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1 Key Insights
2 Report Introduction
3 Key Highlights
4 Executive Summary
5 PD-(L)1 mNSCLC Market Overview at a Glance
6 Key Events
7 Epidemiology and Market Forecast Methodology
8 Disease Background and Overview
9 Diagnosis of NSCLC
10 Current Treatment Practices: NSCLC
11 Treatment Guidelines and Recommendations for NSCLC
12 Epidemiology and Patient Population
13 Patient Journey
14 Key Endpoints in NSCLC
15 Marketed Drugs
16 Emerging Drugs
17 PD-(L)1 mNSCLC: 7MM Market Analysis
18 Unmet Needs
19 SWOT Analysis
20 KOL Views
21 Market Access and Reimbursement
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight

List of Top Selling Market Research Reports in 2024

Surgical Energy Generators Market- https://www.delveinsight.com/report-store/surgical-energy-generators-market
Surgical Sealant Tissue Patch Market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Surgical Stapling Devices Market- https://www.delveinsight.com/report-store/surgical-stapling-devices-market
Vital Sign Monitoring Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Syphilis Market- https://www.delveinsight.com/report-store/syphilis-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Pelvic Organ Prolapse Market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
SGLT2 Inhibitors Market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
Urinary Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/carcinoid-syndrome-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulators Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Skin Neoplasms Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Lymphedema Market- https://www.delveinsight.com/report-store/lymphedema-market
Artificial Disc Market- https://www.delveinsight.com/report-store/artificial-disc-market
Exocrine Pancreatic Insufficiency Market- https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Overactive Bladder Market- https://www.delveinsight.com/report-store/overactive-bladder-oab-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
HDAC Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Facial Lines Market- https://www.delveinsight.com/report-store/facial-lines-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Microscopy Device Market- https://www.delveinsight.com/report-store/microscopy-device-market

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.